Medpace Holdings, Inc. MEDP Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total Revenue by Product | ||||||
| AVAI | $38.02M+22.4% | $38.25M+9.8% | $36.52M-4.9% | $29.11M-25.8% | $31.06M-29.5% | |
| Cardiology | $80.21M+46.1% | $73.18M+48.7% | $65.63M+55.9% | $61.13M+31.4% | $54.9M+24.4% | |
| Central Nervous System | $56.26M-3.5% | $63.04M+8.1% | $59.47M+6.6% | $58.58M-3.5% | $58.28M+4.7% | |
| Metabolic | $201.24M+18.0% | $195.92M+16.5% | $192.64M+16.8% | $188.56M+15.7% | $170.48M+9.8% | |
| Oncology | $237.56M+60.5% | $249.81M+103% | $199.26M+59.7% | $147.87M+39.1% | $148.02M+42.8% | |
| Other | $93.32M-2.6% | $88.25M-14.5% | $106.4M-0.9% | $118.06M+5.0% | $95.84M-11.6% | |
| Total direct costs by Product | ||||||
| Direct Costs | $198.27M+11.5% | $182.15M+8.7% | $186.34M+8.6% | $185.83M+8.3% | $177.82M+3.7% | |
| Reimbursed out-of-pocket expenses | $312M+54.1% | $320.98M+68.3% | $276.63M+43.5% | $237.47M+17.1% | $202.4M+9.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Medpace Holdings, Inc. break its business down?
- Medpace Holdings, Inc. (MEDP) reports total revenue by product across 6 parts — AVAI, Cardiology, Central Nervous System, Metabolic and Oncology. Each is extracted from the segment footnotes and tracked over time.
- Where does Medpace Holdings, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Medpace Holdings, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
